I have to respectfully disagree with you on this one.
I’m not aware of another company moving their cream study into a phase 2 efficacy trial. Nor am I aware of another company moving their Sublingual tablet into a phase 2 efficacy trial for PTSD and Fibromyalgia.
Our Nasal spray animal safety study is to be complete this quarter, and I would assume with the 5 million dollar investor this could be heading to phase 1 human safety trial as early as Q1 2019.
This will result in 3 drugs, all in phase 2 efficacy in different stages in 2020. I have my core shares and will remain long because of this.
The big winner could ultimately be the MM study using a Parenteral delivery system. This also seems to be picking up speed since the 5 million dollar investor showed up.
When I was in Florida at the conference , I was told the cream study would take 18-24 months to complete because the study was expanded, and would keep expanding upon certain milestones, that was in February. We are now at the end of this timeline so I would assume it’s near completion. Did they do a poor job of explaining this to investors through Pr’s? Absolutely! Because I personally would’ve never known this without attending the conference.
With that being said, I’m amazingly confident in 2019 and beyond with this company. Efficacy trials is where it’s at to make money in a BioPharma company.
As always, I wish you and others the best of luck!
